Related Experiment Video
Updated: Jul 10, 2026
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity
Diana Ji1, Stacy L Deeds, Edward J Weinstein
1Sigma-Aldrich, Functional Genomics Operations, St. Louis, MO 63103, USA.
Abstract:
An shRNA tumor suppressor panel was screened using reverse infection of an A549 tumorigenic cell line and exposing it to a predetermined concentration of paclitaxel, an anticancer drug. The shRNAs targeting a positive control gene, MDR1, were found to effectively decrease mRNA levels and cause cells to become more sensitive to the chemotherapeutic drug. A set of genes were identified in the screen of a panel of tumor suppressors which, when down-regulated, were found to increase or decrease cell sensitivity in regards to treatment with paclitaxel. In many cases, there were multiple clones to a single gene that provided a positive result. The shRNAs targeting SMAD4, LZTS2, ST14 and VHL all increased the cell's sensitivity to paclitaxel. The loss of other tumor suppressors such as GLTSCR2, LATS1, NF1, PTEN, TP53 and WT1 induced a protective effect in the cell, making it more resistant to the effect of the drug. Further investigation of VHL mRNA levels after down-regulation with shRNA show a direct correlation between gene expression levels and paclitaxel sensitivity. This study credits the identified genes with the potential to act as prognostic biomarkers for use in genetic profiling, or even as targets in pathways of tumorigenesis yet to be fully understood.
Insights
This study screened tumor suppressor genes using shRNA in A549 cells treated with paclitaxel. Several genes were identified that alter cancer cell sensitivity to this chemotherapy drug, offering potential prognostic biomarkers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer cells often develop resistance to chemotherapy drugs like paclitaxel.
- Identifying genetic factors influencing drug sensitivity is crucial for effective cancer treatment.
Purpose of the Study:
- To screen a panel of tumor suppressor genes for their role in paclitaxel sensitivity in A549 lung cancer cells.
- To identify novel genes that modulate cellular response to chemotherapy.
Main Methods:
- Utilized short hairpin RNA (shRNA) for gene silencing via reverse infection in an A549 tumorigenic cell line.
- Exposed cells to a fixed concentration of the anticancer drug paclitaxel.
- Assessed changes in mRNA levels and cellular sensitivity to paclitaxel.
Main Results:
- Down-regulation of specific tumor suppressors (SMAD4, LZTS2, ST14, VHL) increased paclitaxel sensitivity.
- Loss of other tumor suppressors (GLTSCR2, LATS1, NF1, PTEN, TP53, WT1) conferred resistance to paclitaxel.
- VHL gene expression levels showed a direct correlation with paclitaxel sensitivity.
Conclusions:
- Identified several tumor suppressor genes that significantly impact paclitaxel sensitivity in cancer cells.
- These genes may serve as potential prognostic biomarkers for genetic profiling.
- The identified genes could represent novel therapeutic targets in tumorigenesis pathways.
More Related Videos
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023